Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maulik Patel

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Clinical Pharmacokinetics|March 27, 2025
Pharmacokinetics and Safety of Navitoclax in Hepatic ImpairmentMaulik Patel, Jalaja Potluri, Thomas Marbury, et al.
Frontiers in Oncology|February 17, 2025
Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumorsToshio Shimizu, John Powderly, Albiruni Abdul Razak, et al.
Frontiers in Oncology|November 13, 2024
First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumorsToshio Shimizu, John Powderly, Albiruni Abdul Razak, et al.
Journal for Immunotherapy of Cancer|April 9, 2026
Phase 1b study of ABBV-368, tilsotolimod, budigalimab, and nab-paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinomaAmaury Daste, Xiuning Le, Amani Makkouk, et al.
Genome Announcements|October 30, 2016
Complete Genome Sequence of Brucella abortus SKN 13 Isolated from Placenta of Aborted Cattle in Gujarat, IndiaH C Chauhan, Bharat K Patel, B S Chandel, et al.
Journal for Immunotherapy of Cancer|June 7, 2018
Immune oncology, immune responsiveness and the theory of everythingTolga Turan, Deepti Kannan, Maulik Patel, et al.
Journal for Immunotherapy of Cancer|February 20, 2021
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumorsJason J Luke, Fabrice Barlesi, Ki Chung, et al.
Scientific Data|July 12, 2024
Genetic and multi-omic resources for Alzheimer disease and related dementia from the Knight Alzheimer Disease Research CenterMaria Victoria Fernandez, Menghan Liu, Aleksandra Beric, et al.
Journal for Immunotherapy of Cancer|July 6, 2019
Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshopDavide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, et al.
Journal for Immunotherapy of Cancer|May 23, 2019
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshopDavide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Clinical Pharmacokinetics|March 27, 2025
Pharmacokinetics and Safety of Navitoclax in Hepatic ImpairmentMaulik Patel, Jalaja Potluri, Thomas Marbury, et al.
Frontiers in Oncology|February 17, 2025
Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumorsToshio Shimizu, John Powderly, Albiruni Abdul Razak, et al.
Frontiers in Oncology|November 13, 2024
First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumorsToshio Shimizu, John Powderly, Albiruni Abdul Razak, et al.
Journal for Immunotherapy of Cancer|April 9, 2026
Phase 1b study of ABBV-368, tilsotolimod, budigalimab, and nab-paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinomaAmaury Daste, Xiuning Le, Amani Makkouk, et al.
Genome Announcements|October 30, 2016
Complete Genome Sequence of Brucella abortus SKN 13 Isolated from Placenta of Aborted Cattle in Gujarat, IndiaH C Chauhan, Bharat K Patel, B S Chandel, et al.
Journal for Immunotherapy of Cancer|June 7, 2018
Immune oncology, immune responsiveness and the theory of everythingTolga Turan, Deepti Kannan, Maulik Patel, et al.
Journal for Immunotherapy of Cancer|February 20, 2021
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumorsJason J Luke, Fabrice Barlesi, Ki Chung, et al.
Scientific Data|July 12, 2024
Genetic and multi-omic resources for Alzheimer disease and related dementia from the Knight Alzheimer Disease Research CenterMaria Victoria Fernandez, Menghan Liu, Aleksandra Beric, et al.
Journal for Immunotherapy of Cancer|July 6, 2019
Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshopDavide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, et al.
Journal for Immunotherapy of Cancer|May 23, 2019
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshopDavide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, et al.
Pageof 6